-
公开(公告)号：US11730800B2
公开(公告)日：2023-08-22
申请号：US17024618
申请日：2020-09-17
Applicant: PFIZER INC.
Inventor： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Judith Absalon , Jose Miguel Aste-Amezaga , Johannes Frederik Beeslaar , David Cooper , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Thomas Richard Jones , Isis Kanevsky , Lakshmi Khandke , Paul Liberator , John Lance Perez , Lynn Marie Phelan , Gary Warren Zlotnick
IPC: A61K39/095 , A61K47/64 , C07K14/22 , C07K16/12 , A61K39/00 , A61K47/18 , A61K47/10 , A61K47/26 , A61K31/7028 , A61P31/00 , A61K39/12
CPC classification number: A61K39/095 , A61K31/7028 , A61K39/12 , A61K47/10 , A61K47/183 , A61K47/26 , A61K47/646 , A61K47/6415 , A61P31/00 , C07K14/22 , C07K16/1217 , A61K2039/545 , A61K2039/55 , A61K2039/55505 , A61K2039/6037 , A61K2039/70 , C12N2770/32434
Abstract: In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.
-
2.发明公开公开(公告)号：US20230218735A1
公开(公告)日：2023-07-13
申请号：US18001953
申请日：2021-06-17
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Alexey Vyacheslavovitch Gribenko , William Carl Gruber , Kathrin Ute Jansen , Lakshmi Khandke , Nicholas Randolph Everard Kitchin , Jody Lawrence , Yahong Peng , Michael William Pride , Christopher Frederick Webber , Sabine Susanne Wellnitz , Zhuobiao Yi
CPC classification number: A61K39/08 , A61K47/26 , A61K9/19 , C07K16/1282 , A61P31/04 , A61K2039/55577
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.
-
公开(公告)号：US11680087B2
公开(公告)日：2023-06-20
申请号：US17126712
申请日：2020-12-18
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Rasappa Gounder Arumugham , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Kathrin Ute Jansen , Thomas Richard Jones , Lakshmi Khandke , Bounthon Loun , John Lance Perez , Gary Warren Zlotnick
IPC: A61K39/05 , C07K14/22 , A61K39/00 , A61K39/13 , A61K39/295 , A61K39/095 , A61K39/12 , A61K39/39 , C12N7/00
CPC classification number: C07K14/22 , A61K39/0016 , A61K39/095 , A61K39/12 , A61K39/13 , A61K39/295 , A61K39/39 , C12N7/00 , A61K2039/5252 , A61K2039/545 , A61K2039/55505 , A61K2039/55511 , A61K2039/70 , C12N2710/20034 , C12N2770/32634 , Y02A50/30
Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.
-
公开(公告)号：US20220160859A1
公开(公告)日：2022-05-26
申请号：US17594107
申请日：2020-03-30
Applicant: Pfizer Inc.
Inventor： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Alexey Vyacheslavovitch Gribenko , Nicholas Randolph Everard Kitchin , Paul Liberator , Michael William Pride , Christopher Frederick Webber
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.
-
公开(公告)号：US10813989B2
公开(公告)日：2020-10-27
申请号：US16704701
申请日：2019-12-05
Applicant: PFIZER INC.
Inventor： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Judith Absalon , Jose Miguel Aste-Amezaga , Johannes Frederik Beeslaar , David Cooper , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Thomas Richard Jones , Isis Kanevsky , Lakshmi Khandke , Paul Liberator , John Lance Perez , Lynn Marie Phelan , Gary Warren Zlotnick
IPC: A61K39/095 , A61K31/7028 , A61K47/10 , A61K47/18 , C07K14/22 , C07K16/12 , A61K47/26 , A61K47/64 , A61P31/00 , A61K39/12 , A61K39/00
Abstract: In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.
-
Patent Agency Ranking
公开(公告)号：US20200123206A1
公开(公告)日：2020-04-23
申请号：US16713782
申请日：2019-12-13
Applicant: PFIZER INC.
Inventor： Annaliesa Sybil Anderson , Susan Kay Hoiseth , Kathrin Ute Jansen , Justin Keith Moran , Mark Edward Ruppen
IPC: C07K14/22 , A61K39/095
Abstract: In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.
-
公开(公告)号：US10183070B2
公开(公告)日：2019-01-22
申请号：US15883334
申请日：2018-01-30
Applicant: PFIZER INC.
Inventor： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Judith Absalon , Jose Miguel Aste-Amezaga , Johannes Frederik Beeslaar , David Cooper , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Thomas Richard Jones , Isis Kanevsky , Lakshmi Khandke , Paul Liberator , John Lance Perez , Lynn Marie Phelan , Gary Warren Zlotnick
IPC: A61K39/095 , A61K31/7028 , A61K47/10 , A61K47/18 , C07K14/22 , C07K16/12 , A61K47/26 , A61K47/64 , A61P31/00
Abstract: In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.
-
8.发明申请公开(公告)号：US20180099039A1
公开(公告)日：2018-04-12
申请号：US15286696
申请日：2016-10-06
Applicant: Pfizer Inc.
Inventor： Emilio Anthony Emini , Wendy Jo Watson , Avvari Krishna Prasad , Mingming Han , Jin-Hwan Kim , Jianxin Gu , Yu-ying Yang , Rajesh Kumar Kainthan , David Cooper , Michael William Pride , Kathrin Ute Jansen
CPC classification number: A61K39/092 , A61K47/646 , A61K2039/55505 , A61K2039/6037 , A61K2039/70 , Y02A50/466
Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.
-
公开(公告)号：US20160030543A1
公开(公告)日：2016-02-04
申请号：US14604620
申请日：2015-01-23
Applicant: PFIZER INC.
Inventor： Gary Warren Zlotnick , Susan Kay Hoiseth , Kathrin Ute Jansen , Justin Keith Moran , Mark E. Ruppen , Annaliesa Sybil Anderson , John Erwin Farley , Liesel A. Bernfield
IPC: A61K39/095 , C07K14/22
CPC classification number: A61K39/095 , A61K2039/55577 , A61K2039/6018 , C07K14/22 , C07K16/1217
Abstract: In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.
-
公开(公告)号：US20160017006A1
公开(公告)日：2016-01-21
申请号：US14773324
申请日：2014-03-05
Applicant: PFIZER INC.
Inventor： Deborah Ann Dilts , Annaliesa Sybil Anderson , Kathrin Ute Jansen , Justin Keith Moran , Mark E Ruppen , Eugene Joseph Vidunas
IPC: C07K14/22 , A61K39/095 , A61K39/09 , C07K14/315
CPC classification number: C07K14/22 , A61K39/092 , A61K39/095 , A61K2039/6037 , A61K2039/6068 , C07K14/3156 , C07K2319/00 , C07K2319/55
Abstract: In one aspect, the invention relates to an isolated polypeptide including the amino acid sequence of a carrier polypeptide and the amino acid sequence of an ORF2086 polypeptide. In another aspect, the invention relates to an immunogenic conjugate including ORF2086 polypeptide and a carrier polypeptide. The invention further includes immunogenic compositions and methods for inducing an immune response against Neisseria meningitidis in a mammal.
Abstract translation: 一方面，本发明涉及包含载体多肽的氨基酸序列和ORF2086多肽的氨基酸序列的分离的多肽。 另一方面，本发明涉及包含ORF2086多肽和载体多肽的免疫原性缀合物。 本发明还包括用于在哺乳动物中诱导针对脑膜炎奈瑟氏球菌的免疫应答的免疫原性组合物和方法。
-
-
-
-
-
-
-
-
-
Search Results
74
records
(took 0.044 seconds)
